查詢結果分析
相關文獻
- P2Y₁₂抑制劑於急性冠心症之治療
- 以臨床實用觀點論急救流程之改變
- 2000年緊急心臟照護之新改變
- 急性冠心症治療之新趨勢
- 低分子量肝素(Low-Molecular-Weight Heparin)在非ST-波段上升型急性冠心症的應用
- 無ST波上升之心肌梗塞案例報告與用藥評估
- Troponins的迷思
- 抗血小板凝集新藥--Ticagrelor
- 慢性腎衰竭病患心血管疾病之治療
- Survival of Patients with Acute Coronary Syndrome Who Receive Secondary Prevention Therapy: A Single-center Cohort Study
頁籤選單縮合
題 名 | P2Y₁₂抑制劑於急性冠心症之治療=P2Y₁₂ Inhibitors for Acute Coronary Syndrome |
---|---|
作 者 | 蔡玉娟; 陳芊卉; 簡素玉; | 書刊名 | 藥學雜誌 |
卷 期 | 29:3=116 2013.09[民102.09] |
頁 次 | 頁52-56 |
分類號 | 418.23 |
關鍵詞 | 急性冠心症; P2Y₁₂抑制劑; Ticagrelor; Prasugrel; |
語 文 | 中文(Chinese) |
中文摘要 | 併用 aspirin 及 P2Y12抑制劑之雙重抗血小板藥是急性冠心症及冠狀動脈支架置放術後預防再次心血管事件之標準治療。Clopidogrel 是目前最常使用的 P2Y12 (purinergic receptor P2Y, G-protein coupled,12) 抑制劑,而新一代 P2Y12血小板抑制劑如 ticagrelor 和 prasugrel,起始作用時間較 clopidogrel 快速,更能抑制血小板活性,進而改善重大心血管事件,但相對而言出血發生率也較高。美國和歐洲心臟學會在最新急性冠心症指引中對 P2Y12抑制劑選用提出建議,與 aspirin 併用雙重抗血小板藥品策略中,ticagrelor 建議用於所有中度至高度缺血性風險患者,而 prasugrel 限用於接受冠狀動脈介入性治療且不曾用過 P2Y12抑制劑之患者。Ticagrelor 和 prasugrel 在冠心症患者預防缺血性事件上可作為 clopidogrel 之有效替代用藥。 |
英文摘要 | Antiplatelet therapy is the cornerstone of management of acute coronary syndromes (ACS). Dual-antiplatelet therapy of aspirin plus P2Y12 inhibitor is the foundation of treatment to prevent thrombotic complications of ACS and undergoing a coronary stenting procedure. Clopidogel is the most utilized drug that inhibits P2Y12 in platelet. Compared to clopidogrel, the new P2Y12 inhibitors prasugrel and ticagrelor are more potent, more rapid, and more effective in improving major cardiovascular events, with a tendency to increase bleeding. Prasugrel and ticagrelor have been added to updated ACC/AHA and ESC guideline for ACS patients. According to the guidelines, ticagrelor is recommended for all patients at moderate to high risk of ischemic events, and prasugrel is restrictive in P2Y12 inhibitor-naïve patients undergoing PCI. Ticagrelor and prasugrel are effective alternative to clopidogrel for the prevention of ischemic events in ACS patients. |
本系統中英文摘要資訊取自各篇刊載內容。